Daily Media Digest June 14, 2022

Canada becomes first country to approve experimental ALS drug treatment Albrioza
Global News
“The ALS Society of Canada estimates that 3,000 Canadians live with the incurable motor neuron disease that leads to paralysis, the inability to …”
TAGS: innovative research, experimental drug, ALS Society of Canada

Study explores the promising but still puzzling field of stem cell therapy for painful joint injuries

University of Calgary
“He is the Canada Research Chair (Tier II) in Bone and Joint Stem Cell Biology. Dr. William Brent Edwards, PhD, is an associate professor in the …”
TAGS: stem cell therapy, regenerative-medicine, chronic pain, University of Calgary

All breast cancer patients don’t need radiotherapy, researchers find

McMaster University
“Older women with early-stage breast cancer may not need radiotherapy after undergoing surgery, McMaster researcher Timothy Whelan and his team have found.”
TAGS: breast cancer, radiotherapy, breast-conserving surgery, McMaster University

Able Innovations works to transform frontline healthcare with USD $6MM in funding

“… including the U.S. Veterans Health Administration (VHA), Toronto’s University Health Network (UHN), and Ottawa’s Élisabeth Bruyère Hospital.”
TAGS: patient transfers, medtech, University Health Network, University of Waterloo

Cold and flu viruses showed up later this year – TBNewsWatch.com

“At Thunder Bay Regional Health Sciences Centre, chief of staff Dr. Bradley Jacobson said there’s been an increase in visits to the emergency …”
TAGS: upper respiratory tract infections, cold or flu-like symptoms, Thunder Bay Regional Health Sciences Centre

GlycoNet partner company, Alectos Therapeutics, enters ground-breaking $700 million agreement with Biogen

HRI Portal
“GlycoNet, one of the world’s leaders in glycomics – the study of carbohydrates in all living organisms– is pleased to announce that their partner company, Alectos Therapeutics has entered into a $700 million licensing and collaboration agreement with Biogen.”
TAGS: glycomics research and innovation, neurological diseases, GlycoNet